Filings

6 documents · 37 matches

1. ESLA Estrella Immunopharma, Inc. 10-K 2026-03-18

   Item 1A. Risk Factors.

   material weaknesses in its internal control over financial reporting, such material weaknesses could result in inaccuracies in Estrella’s consolidated
   8 matches in this document Show context Copy citation

2. ESLA Estrella Immunopharma, Inc. 10-Q 2026-08-13

   Item 4. Controls and Procedures

   material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board Auditing
   5 matches in this document Show context Copy citation

3. ESLA Estrella Immunopharma, Inc. 10-Q 2026-05-18

   Item 4. Controls and Procedures

   material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board Auditing
   6 matches in this document Show context Copy citation

4. ESLA Estrella Immunopharma, Inc. 10-Q 2025-11-12

   Item 4. Controls and Procedures

   material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board Auditing
   6 matches in this document Show context Copy citation

5. ESLA Estrella Immunopharma, Inc. 10-Q 2025-08-12

   Item 4. Controls and Procedures

   material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board Auditing
   6 matches in this document Show context Copy citation

6. ESLA Estrella Immunopharma, Inc. 10-Q 2025-05-14

   Item 4. Controls and Procedures

   material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board Auditing
   6 matches in this document Show context Copy citation